Management of bleeding in patients with advanced cancer

Oncologist

Volumn 9, Issue 5, 2004, Pages 561-570

  Pereira, Jose ^a,b   Phan, Tien ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b FOOTHILLS HOSPITAL   (Canada)

Author keywords

Bleeding; Cancer; Hemorrhaging; Palliative

Indexed keywords

ACETONE; ADRENALIN; AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR; COCAINE; DESMOPRESSIN; FORMALDEHYDE; FRESH FROZEN PLASMA; HEMOSTATIC AGENT; MENADIOL; MIDAZOLAM; OCTREOTIDE; PHYTOMENADIONE; PROSTAGLANDIN E2; PROSTAGLANDIN F2; SILVER NITRATE; SOMATOSTATIN; SUCRALFATE; TERLIPRESSIN; THROMBIN; THROMBOPLASTIN; TRANEXAMIC ACID; VASOPRESSIN; VITAMIN K GROUP; WARFARIN;

ABDOMINAL PAIN; ADVANCED CANCER; ANAPHYLAXIS; ARTIFICIAL EMBOLISM; BLEEDING; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; CYANOSIS; DIARRHEA; DYSPNEA; HEMOSTASIS; HUMAN; HYPOTENSION; LIGATION; NAUSEA; PRIORITY JOURNAL; REVIEW; VOMITING; WOUND DRESSING;

ANTIFIBRINOLYTIC AGENTS; BANDAGES; BLOOD TRANSFUSION; ENDOSCOPY; HEMORRHAGE; HEMOSTATIC TECHNIQUES; HUMANS; NEOPLASMS; RADIOTHERAPY; SOMATOSTATIN; TERMINAL CARE; VASOPRESSINS; VITAMIN K;

EID: 4944266627     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.9-5-561     Document Type: Review

References (116)

1. Pereira J, Mancini I, Bruera E. The management of bleeding in patients with advanced cancer. In: Portenoy RK, Bruera E, eds. Topics in Palliative Care, Volume 4. New York: Oxford University Press, 2000:163-183.
2. Gagnon B, Mancini I, Pereira J et al. Palliative management of bleeding events in advanced cancer patients. J Palliat Care 1998;14:50-54.
3. Hoskin P, Makin W. The role of surgical and radiological intervention in palliation. In: Oncology for Palliative Medicine. Oxford, UK: Oxford University Press, 1998:229-234.
4. Dutcher JP. Hematologic abnormalities in patients with non-hematologic malignancies. Hematol Oncol Clin North Am 1987;1:281-299.
5. Schafer AI. Effects of nonsteroidal anti-inflammatory therapy on platelets. Am J Med 1999;106:258-368.
6. Hutten BA, Prins MH, Gent M et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000;18:3078-3083.
7. Jamjian MC. Bleeding problems in palliative care patients. Evidence based symptom control in palliative care. In: Lipman AG. Jackson KC, Tyler LS, eds. Systemic Reviews and Validated Clinical Practice Guidelines for 15 Common Problems in Patients with Life Limiting Disease. Binghamton, NY: The Haworth Press Inc., 2000:37-46.
8. Pringle MB, Beasley P, Brightwell AP. The use of Merocel nasal packs in the treatment of epistaxis. J Laryngol Otol 1996;110:543-546.
9. Tisseel Kit VH. Compendium of Pharmaceuticals and Specialties. Ottawa, Canada: Canadian Pharmacists Association, 1996;31:1479-1480.
10. Patsner B. Topical acetone for control of life-threatening vaginal hemorrhage from recurrent vaginal gynaecological cancer. Eur J Gynaecol Oncol 1993;1433-1435.
11. Sirlak M, Eryilmaz S, Yazicioglu L et al. Comparative study of microfibrillar collagen hemostat (Colgel) and oxidized cellulose (Surgicel) in high transfusion-risk cardiac surgery. J Thorac Cardiovasc Surg 2003;126:666-670.
12. Atkinson LJ, Fortunate NH, eds. Hemostasis and blood loss replacement. In: Operating Room Technique, Eighth Edition. St. Louis, MO: Mosby. 1996:469-489.
13. Schenk WG 3rd, Burks SG, Gagne PJ et al. Fibrin sealant improves hemostasis in peripheral vascular surgery: a randomized prospective trial. Ann Surg 2003;237:871-876.
14. Thomas S. Alginate dressings in surgery and wound management: Part 2. Wound Care 2000;9:115-119.
15. Woodruff R. Haematological problems. In: Woodruff R, ed. Palliative Medicine: Symptomatic and Supportive Care for Patients with Advanced Cancer and AIDS. Melbourne, Australia: Aperula Pty Ltd., 1993:228-252.
16. Thrombostat. Compendium of Pharmaceuticals and Specialties. Ottawa, Canada: Canadian Pharmacists Association, 1997:32:1587.
17. Gall RM, Witterick IJ, Shargill NS et al. Control of bleeding in endoscopic sinus surgery: use of a novel gelatin-based hemostatic agent. J Otolaryngol 2002;31:271-274.
18. Weaver FA, Hood DB, Zatina M et al.. Gelatin-thrombin-based hemostatic sealant for intraoperative bleeding in vascular surgery. Ann Vasc Surg 2002;16:286-293.
19. Harris WH, Crothers OD, Moyen BJ et al. Topical hemostatic agents for bone bleeding in humans. A quantitative comparison of gelatin paste, gelatin sponge plus bovine thrombin, and microfibrillar collagen. J Bone Joint Surg Am 1978;60:454-456.
20. Shinkwin CA, Beasley N, Simo R et al. Evaluation of surgicel Nu-knit, Merocel and Vasolene gauze nasal packs: a randomized trial. Rhinology 1996;34:41-43.
21. Mankad PS, Codispoti M. The role of fibrin sealants in hemostasis. Am J Surg 2001;182(suppl 2):21S-28S.
22. Russo P. Urologic emergencies. In: Devita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. Philadelphia, PA: JB Lippincott Co., 1993:2159-2160.
23. Vijan SR, Keating MA, Althausen AF. Ureteral stenosis after silver nitrate instillation in the treatment of essential hematuria. J Urol 1988;139:1015-1016.
24. Roche B, Chautems R, Marti MC. Application of formaldehyde for treatment of hemorrhagic radiation-induced proctitis. World J Surg 1996;20:1092-1094; discussion 1094-1095.
25. Biswal BM, Lal P, Rath GK et al. Intrarectal formalin application, an effective treatment for grade III haemorrhagic radiation proctitis. Radiother Oncol 1995;35:212-215.
26. Yegappan M, Ho YH, Nyam D et al. The surgical management of colorectal complications from irradiation for carcinoma of the cervix. Ann Acad Med Singapore 1998:27:627-630.
27. Brundage MD, Bezjak A, Dixon P et al. The role of palliative thoracic radiotherapy in non-small cell lung cancer. Can J Oncol 1996;6(suppl 1):25-32.
28. A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Medical Research Council Lung Cancer Working Party. Br J Cancer 1992;65:934-941.
29. Hoskin PJ. Radiotherapy in symptom management. In: Doyle D, Hanks GWC, Macdonald N, eds. Second Edition. New York: Oxford University Press, 1998:278-280.
30. Langendijk JA, ten Velde GP, Aaronson NK et al. Quality of life after palliative radiotherapy in non-small cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys 2000:47:149-155.
31. Rees GJ, Devrell CE, Barley VL et al. Palliative radiotherapy for lung cancer: two versus five fractions. Clin Oncol (R Coll Radiol) 1997;9:90-95.
32. Stevens MJ, Begbie SD. Hypofractionated irradiation for inoperable non-small cell lung cancer. Australas Radiol 1995;39:265-270.
33. Sundstrom S, Bremnes RM, Aasebo U et al. Hypofractionated palliative radiotherapy (17Gy/2fractions) is comparable with standard fractionation in advanced non-small cell lung cancer. Results from a national phase 111 trial. J Clin Oncol 2004:5:801-810.
34. Biswal BM, Lal P, Rath GK et al. Hemostatic radiotherapy in carcinoma of the uterine cervix. Int J Gynaecol Obstet 1995;50:281-285.
35. Miller CM, O'Neill A, Mortimer PS. Skin problems in palliative care: nursing aspects. In: Doyle D, Hanks GWC, eds. Oxford Textbook of Palliative Medicine. New York: Oxford University Press, 1993:395-407.
36. Srinivasan V, Brown CH, Turner AG. A comparison of two radiotherapy regimens for the treatment of symptoms from advanced bladder cancer. Clin Oncol (R Coll Radiol) 1994;6:11-13.
37. Ferris FD, Bezjak A, Rosenthal SG. The palliative uses of radiation therapy in surgical oncology patients. Surg Oncol Clin North Am 2001;10:185-201.
38. MacDougall RH, Munro AJ, Wilson JA. Palliation in head and neck cancer. In: Doyle D, Hanks GWC, eds. Oxford Textbook of Palliative Medicine. New York: Oxford University Press, 1993:422-433.
39. Burnett DA, Rikkers LF. Nonoperative emergency treatment of variceal hemorrhage. Surg Clin North Am 1990;70:291-306.
40. Akhtar K, Byrne JP, Bancewicz J et al. Argon beam plasma coagulation in the management of cancers of the esophagus and stomach. Surg Endosc 2000;14:1127-1130.
41. Loftus EV, Alexander GL, Ahlquist DA et al. Endoscopic treatment of major bleeding from advanced gastroduodenal malignant lesions. Mayo Clin Proc 1994;69:736-740.
42. Knott-Craig CJ, Oostuizen JG, Rossouw G et al. Management and prognosis of massive hemoptysis: recent experience with 120 patients. J Thorac Cardiovasc Surg 1993;105:394-397.
43. Kvale PA, Simoff M, Prakash UB. Lung cancer. Palliative care. Chest 2003;123(suppl 1):284S-311S.
44. Patel U, Pattison CW, Raphael M. Management of massive haemoptysis. Br J Hosp Med 1994;52:74, 76-78.
45. MacKinnon KJ, Norman RW. Genitourinary disorders in palliative medicine. In: Doyle D, Hanks GWC, eds. Oxford Textbook of Palliative Medicine. New York: Oxford University Press, 1993:415-422.
46. Loscos JM, Calvo E, Alvarez-Sala JL et al. Treatment of dysphagia and massive hemorrhage in esophageal carcinoma by ethanol injection. Endoscopy 1993;25:544.
47. Gupta PK, Fleischer DE. Nonvariceal upper gastrointestinal bleeding. Med Clin North Am 1993;77:973-992.
48. Tajika M, Kato T, Magaki M et al. Endoscopic injection of gelatin solution for severe hemorrhagic gastric cancer. Gastrointest Endosc 1996;43:247-250.
49. Savides TJ, Jensen DM, Cohen J et al. Severe upper gastrointestinal tumor bleeding: endoscopic findings, treatment, and outcome. Endoscopy 1996;28:244-248.
50. Suzuki H, Miho O, Watanabe Y et al. Endoscopic laser therapy in the curative and palliative treatment of upper gastrointestinal cancer. World J Surg 1989;13:158-164.
51. Mathus-Vliegen EMH, Tytgat GN. Analysis of failures and complications of neodymium:YAG laser photocoagulation in gastrointestinal tract tumors: a retrospective survey of 18 years' experience. Endoscopy 1990;22:17-23.
52. Kato R, Sawafuji M, Kawamura M et al. Massive hemoptysis successfully treated by modified bronchoscopic balloon tamponade technique. Chest 1996;109:842-843.
53. Bono MJ. Lower gastrointestinal tract bleeding. Emerg Med Clin North Am 1996;14:547-556.
54. Schulze S, Lyng KM. Palliation of rectosigmoid neoplasms with Nd:YAG laser treatment. Dis Colon Rectum 1994;37:882-884.
55. Schrock TR. Colonoscopic diagnosis and treatment of lower gastrointestinal bleeding. Surg Clin North Am 1989;69:1309-1325.
56. Broadley KE, Kurowska A, Dick R et al. The role of embolization in palliative care. Palliat Med 1995;9:331-335.
57. Bates MC, Shamsham FM. Endovascular management of impending carotid rupture in a patient with advanced head and neck cancer. J Endovasc Ther 2003;10:54-57.
58. Sakakibara Y, Kuramoto K, Jikuya T et al. An approach for acute disruption of large arteries in patients with advanced cervical cancer: endoluminal balloon occlusion technique. Ann Surg 1998;227:134-137.
59. Morrissey DD, Andersen PE, Nesbit GM et al. Endovascular management of hemorrhage in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 1997;123:15-19.
60. Nabi G, Sheikh N, Greene D et al. Therapeutic transcatheter arterial embolization in the management of intractable haemorrhage from pelvic urological malignancies: preliminary experience and long-term follow-up. BJU Int 2003;92:245-247.
61. Wells I. Internal iliac artery embolization in the management of pelvic bleeding. Clin Radiol 1996;51:825-827.
62. Yamashita Y, Harada M, Yamamoto H et al. Transcatheter arterial embolization of obstetric and gynaecological bleeding: efficacy and clinical outcome. Br J Radiol 1994;67:530-534.
63. Hays MC, Wilson NM, Page A et al. Selective embolization of bladder tumours. Br J Urol 1996;78:311-312.
64. Jenkins CN, McIvor J. Survival after embolization of the internal iliac arteries in ten patients with severe haematuria due to recurrent pelvic carcinoma. Clin Radiol 1996;51:865-868.
65. Kawaguchi T, Tanaka M, Itano S et al. Successful treatment of bronchial bleeding from invasive pulmonary metastasis of hepatocellular carcinoma: a case report. Hepatogastroenterology 2001;48:851-853.
66. Recordare A, Bonariol L, Caratozzolo E et al. Management of spontaneous bleeding due to hepatocellular carcinoma. Minerva Chir 2002;57:347-356.
67. Srivastava DN, Gandhi D, Julka PK et al. Gastrointestinal hemorrhage in hepatocellular carcinoma: management with transhepatic arterioembolization. Abdom Imaging 2000;25:380-384.
68. Wu JX, Huang JF, Yu ZJ et al. [Factors related to acute upper gastrointestinal bleeding after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.] Ai Zheng 2002;21:881-884. Chinese.
69. Witz M, Korzets Z, Shnaker A et al. Delayed carotid artery rupture in advanced cervical cancer: a dilemma in emergency management. Eur Arch Otorhinolaryngol 2002;259:37-39.
70. Baum M, Breach NM, Shepherd JH et al. Surgical palliation. In: Doyle D, Hanks GWC, eds. Oxford Textbook of Palliative Medicine. New York: Oxford University Press, 1993:129-140.
71. Whitling AM, Bussey HI, Lyons RM. Comparing different routes and doses of phytonadione for reversing excessive anticoagulation. Arch Intern Med 1998;158:2136-2140.
72. Byrd DC, Stephens MA, Hammann GL et al. Subcutaneous phytonadione for reversal of warfarin-induced elevation of the International Normalized Ratio. Am J Health Syst Pharm 1999;56:2312-2315.
73. Raj G, Kumar R, McKinney WP. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. Arch Intern Med 1999;159:2721-2724.
74. Nee R, Doppenschmidt D, Donovan DJ et al. Intravenous versus subcutaneous vitamin K1 in reversing excessive oral anticoagulation. Am J Cardiol 1999;83:286-288, A6-A7.
75. Shields RC, McBance RD, Kuiper JD et al. Efficacy and safety of intravenous phytonadione (vitamin K1) in patients on long-term oral anticoagulant therapy. Mayo Clinic Proc 2001;76:260-266.
76. Fiore LD, Scola MA, Cantillon CE et al. Anaphylactoid reactions to vitamin K. J Thromb Thrombolysis 2001;11:175-183.
77. Patel RJ, Witt DM, Saseen JJ et al. Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation. Pharmacotherapy 2000;20:1159-1166.
78. Fondevila CG, Grosso SH, Santarelli MT et al. Reversal of excessive oral anticoagulation with a low oral dose of vitamin K1 compared with acenocoumarine discontinuation. A prospective, randomized, open study. Blood Coagul Fibrinolysis 2001;12:9-16.
79. Green B, Cairns S, Harvey R et al. Phytomenadione or menadiol in the management of an elevated international normalized ratio (prothrombin time). Aliment Pharmacol Ther 2000;14:1685-1689.
80. Stein C, Korula J. Variceal bleeding. What are the treatment options? Postgrad Med 1995;98:143-146, 149-152.
81. Gross M, Schiemann U, Muhlhofer A et al. Meta-analysis: efficacy of therapeutic regimens in ongoing variceal bleeding. Endoscopy 2001;33:737-746.
82. D'Amico G, Pietrosi G, Tarantino I et al. Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: a Cochrane meta-analysis. Gastroenterology 2003;124:1277-1291.
83. Allum WH, Brearley S, Wheatley KE et al. Acute haemorrhage from gastric malignancy. Br J Surg 1990;77:19-20.
84. Lin HJ, Perng CL, Wang K et al. Octreotide for arrest of peptic ulcer hemorrhage-a prospective, randomized controlled trial. Heptogastroenterology 1995;42:856-860.
85. Lamberts SW, van der Lely AJ, de Herder et al. Octreotide. N Engl J Med 1996;334:246-254.
86. Burroughs AK, McCormick PA, Hughes MD et al. Randomized, double-blind, placebo-controlled trial of somatostatin for variceal bleeding: emergency control and prevention of early variceal rebleeding. Gastroenterology 1990;99:1388-1395.
87. Halloran CM, Ghaneh P, Bosonnet L et al. Complications of pancreatic cancer resection. Dig Surg 2002;19:138-146.
88. Dean A, Tuffin P. Fibrinolytic inhibitors for cancer-associated bleeding problems. J Pain Symptom Manage 1997;13:20-24.
89. Garewal HS, Durie BG. Anti-fibrinolytic therapy with aminocaproic acid for the control of bleeding in thrombocytopenic patients. Scand J Haematol 1985;35:497-500.
90. Fricke W, Alling D, Kimball J et al. Lack of efficacy of tranexamic acid in thrombocytopenic bleeding. Transfusion 1991;31:345-348.
91. Cada DJ, ed. Drug Facts and Comparisons. St. Louis: Wolters Kluwer Health, 1997:91.
92. Herfindal ET, Gourley DR, eds. Textbook of Therapeutics: Drug and Disease Management, Sixth Edition. Baltimore: Williams and Wilkins, 1996.
93. Ramstrom G, Sindet-Pedersen S, Hall G et al. Prevention of postsurgical bleeding in oral surgery using tranexamic acid without dose modification or oral anticoagulants. J Oral Maxillofac Surg 1993;51:1211-1216.
94. Chandra B. Treatment of subarachnoid haemorrhage from ruptured intracranial aneurysm with tranexamic acid: a double-blind clinical trial. Ann Neurol 1978;3:502-504.
95. Biggs JC, Hugh TB, Dodds AJ. Tranexamic acid and upper gastrointestinal haemorrhage: a double-blind trial. Gut 1976;17:729-734.
96. De Boer WA, Koolen MGJ, Roos CM et al. Tranexamic acid treatment of haemothorax in two patients with malignant mesothelioma. Chest 1991;100:847-848.
97. Kaufman B, Wise A. Antifibrinolytic therapy for haemoptysis related to bronchial carcinoma. Postgrad Med J 1993;69:80-81.
98. Cooper DL, Sandier AB, Wilson LD et al. Disseminated intravascular coagulation and excessive fibrinolysis in a patient with metastatic prostate cancer: response to epsilon-aminocaproic acid. Cancer 1992;70:656-658.
99. Shpilberg O, Blumenthal R, Sofer O et al. A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. Leuk Lymphoma 1995;19:141-144.
100. Avvisati G, Buller HR, ten Gate JW et al. Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet 1989;2:122-124.
101. Hashimoto S, Koike T, Tatewaki W et al. Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage. Leukemia 1994;8:1113-1115.
102. Woo KS, Tse LK, Woo JL et al. Massive pulmonary thromboembolism after tranexamic acid antifibrinolytic therapy. Br J Clin Pract 1989;43:465-466.
103. McElligott E, Quigley C, Hanks GW. Tranexamic acid and rectal bleeding. Lancet 1991;337:431.
104. Erstad BL. Systemic hemostatic medications for reducing surgical blood loss. Ann Pharmacother 2001;35:925-934.
105. Aderka D, Praff G, Santo M et al. Bleeding due to thrombocytopenia in acute leukemias and reevaluation of the prophylactic platelet transfusion policy. Am J Med Sci 1986;291:147-151.
106. Lassauniere JM, Bertolino M, Hunault M et al. Platelet transfusions in advanced hematological malignancies: a position paper. J Palliat Care 1996;12:38-41.
107. Pisciotto PT, Benson K, Hume H et al. Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients. Transfusion 1995;35:498-502.
108. Beutler E. Platelet transfusions: the 20,000/μl trigger. Blood 1993;81:1411-1413.
109. Schiffer CA. Prophylactic platelet transfusion. Transfusion 1992;32:295-298.
110. Söhngen D, Schneider W. [Thrombocyte transfusion: clinical aspects, follow-up and complications.] Klin Wochenschr 1991;69:379-386. German.
111. Gleeson C, Spencer D. Blood transfusion and its benefits in palliative care. Palliat Med 1995;9:307-313.
112. Monti M, Castellani L, Berlusconi A et al. Use of red blood cell transfusions in terminally ill cancer patients admitted to a palliative care unit. J Pain Symptom Manage 1996;12:18-22.
113. Johnson MJ. Problem of anticoagulation within a palliative care setting: an audit of hospice patients taking warfarin. Palliat Med 1997;11:306-312. Erratum in: Palliat Med 1998:12:463.
114. Johnson MJ. Problem of anticoagulation within a palliative care setting: an audit of hospice patients taking warfarin. Palliat Med 1997;11:306-312. Erratum in: Palliat Med 1998:12:463.
115. Johnson MJ, Sherry K. How do palliative physicians manage venous thromboembolism? Palliat Med 1997;11:462-468.
116. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688-698.